Royalty Pharma (RPRX) Cash & Current Investments (2019 - 2026)

Royalty Pharma has disclosed Cash & Current Investments across 8 years of filings, most recently posting $608.3 million for Q1 2026.

• Cash & Current Investments for Q1 2026 came in at $608.3 million, down 44.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $608.3 million (down 44.69% YoY), and the FY2025 annual result was $637.5 million, down 35.43% from the prior year.
• Cash & Current Investments came in at $608.3 million for Q1 2026 at Royalty Pharma, down from $637.5 million in the prior quarter.
• In the past five years, Cash & Current Investments ranged from a high of $2.5 billion in Q2 2022 to a low of $495.3 million in Q4 2023.
• The 5-year median for Cash & Current Investments is $998.6 million (2024), against an average of $1.3 billion.
• Across the five-year window, Cash & Current Investments soared 138.58% in 2022 and tumbled 71.07% in 2023, its largest moves.
• Royalty Pharma's Cash & Current Investments stood at $1.7 billion in 2022, then sank by 71.07% to $495.3 million in 2023, then soared by 99.31% to $987.2 million in 2024, then slumped by 35.43% to $637.5 million in 2025, then fell by 4.58% to $608.3 million in 2026.
• The last three Cash & Current Investments figures came in at $608.3 million (Q1 2026), $637.5 million (Q4 2025), and $955.0 million (Q3 2025), per Business Quant data.